UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
April 10, 2020
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as
specified in its charter)
|
DELAWARE
|
|
41-1505029
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
|
|
29 Emmons Drive,
Suite B-10
Princeton, NJ
|
|
08540
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
(609) 538-8200
|
|
(Issuer’s telephone number, including area code)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $.001 per share
|
|
SNGX
|
|
The Nasdaq Capital Market
|
|
Common Stock Purchase Warrants
|
|
SNGXW
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
As previously disclosed, on August 11,
2017, Soligenix, Inc. (the “Company”) and FBR Capital Markets & Co. (now known as B. Riley FBR, Inc.) (“FBR”)
entered into an At Market Issuance Sales Agreement (the “Sales Agreement”), pursuant to which the Company may sell
from time to time, at its option, shares of its common stock through FBR, as sales agent. Sales of common stock made pursuant to
the Sales Agreement, if any, will be made in “at the market offerings” as defined in Rule 415 under the Securities
Act of 1933, as amended, on or through The NASDAQ Capital Market (“Nasdaq”), pursuant to the Company’s effective
shelf registration statement on Form S-3 (File No. 333-217738) filed on May 5, 2017 with the U.S. Securities and Exchange Commission
(the “SEC”), the base prospectus filed as part of such registration statement, and the prospectus supplement dated
April 10, 2020 filed by the Company with the SEC. In accordance with the terms of the Sales Agreement, under the prospectus supplement
dated April 10, 2020, the Company, having no contractual obligation to do so, may offer and sell shares of the Company’s common stock having an aggregate offering price
of up to $10.2 million, from time to time.
On October 3, 2018, the Company filed a
prospectus supplement for sale of up to $9.0 million of shares of common stock pursuant to the Sales Agreement and the Company
sold an aggregate of approximately $8.15 million of shares thereunder. The prospectus supplement filed on April 10, 2020, supersedes
the prospectus supplement dated October 3, 2018, and no additional shares will be offered or sold pursuant to the prospectus supplement
dated October 3, 2018.
This Current Report on Form 8-K shall not
constitute an offer to sell or the solicitation of an offer to buy any security nor shall there be any sale of these securities
in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such state.
Additional information with respect to
the Sales Agreement is available under “Item 5 – Other Information” in the Company’s Quarterly Report on
Form 10-Q filed on August 11, 2017 and is incorporated herein by reference. The description of the Sales Agreement presented here
does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement which is filed as Exhibit
10.1 to the Company’s Quarterly Report on Form 10-Q filed on August 11, 2017. The opinion of the Company’s counsel
regarding the validity of the shares that will be issued pursuant to the Sales Agreement under the prospectus supplement filed
on April 10, 2020 is filed herewith as Exhibit 5.1.
This report contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the
Company’s judgment as of the date of this report. Such forward-looking statements include statements regarding the ability
to sell shares and raise additional funds pursuant to the Sales Agreement. Such forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from predicted or expected results. The inclusion of forward-looking statements
should not be regarded as a representation by the Company that any of these results will be achieved. Actual results may differ
from those set forth in this report due to the risks and uncertainties associated with market conditions and the satisfaction of
pre-sale conditions under the Sales Agreement, as well as risks and uncertainties inherent in the Company’s business, including
those described in the Company’s periodic filings with the SEC. These forward-looking statements are made only as the date
hereof, and, except as required by law, the Company undertakes no obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety
by this cautionary statement.
Item 9.01. Financial Statements
and Exhibits.
(d) Exhibits.
|
|
(1)
|
Incorporated by reference to Exhibit 10.1 to the Company’s
Quarterly Report on Form 10-Q filed on August 11, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Soligenix, Inc.
|
|
April 10, 2020
|
By:
|
/s/ Christopher J. Schaber
|
|
|
|
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
|
EXHIBIT INDEX
|
|
(1)
|
Incorporated by reference to Exhibit 10.1 to the Company’s
Quarterly Report on Form 10-Q filed on August 11, 2017.
|
3
Exhibit 5.1
NEW
YORK
LONDON
SINGAPORE
PHILADELPHIA
CHICAGO
WASHINGTON, DC
SAN FRANCISCO
SILICON VALLEY
SAN DIEGO
LOS ANGELES
TAIWAN
BOSTON
HOUSTON
AUSTIN
HANOI
HO CHI MINH CITY
|
FIRM
and AFFILIATE OFFICES
www.duanemorris.com
|
SHANGHAI
ATLANTA
BALTIMORE
WILMINGTON
MIAMI
BOCA RATON
PITTSBURGH
NEWARK
LAS VEGAS
CHERRY HILL
LAKE TAHOE
MYANMAR
OMAN
A GCC REPRESENTATIVE OFFICE
OF DUANE MORRIS
ALLIANCES IN MEXICO
AND SRI LANKA
|
April 10, 2020
Soligenix, Inc.
Attn: Board of Directors
29 Emmons Drive, Suite B-10
Princeton, NJ 08540
|
|
Re:
|
Soligenix, Inc. (the “Corporation”)
|
Form S-3 (Registration File No. 333-217738)
(the “Registration
Statement”), as supplemented
by the Prospectus Supplement
dated April 10, 2020 (the “Prospectus
Supplement”)
Ladies and Gentlemen:
We have acted as
special counsel to the Corporation in connection with the preparation and filing with the U.S. Securities and Exchange
Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), of
the Registration Statement as supplemented by the Prospectus Supplement, relating to the offer and sale by the Corporation of
shares of common stock, $0.001 par value, of the Corporation having an aggregate gross sales price of up to $10.2 million
(the “Shares”), pursuant to the terms of the At Market Issuance Sales Agreement dated as of August 11, 2017
between the Corporation and FBR Capital Markets & Co. (now known as B. Riley FBR, Inc.), as sales agent (the
“Agreement”).
As counsel to the Corporation,
we have supervised all corporate proceedings in connection with the preparation and filing of the Registration Statement as supplemented
by the Prospectus Supplement.
|
Duane
Morris llp
|
|
1875 NW
Corporate blvd., suite 300 boca Raton, Fl 33431-8561
|
PHONE: 561.962.2100 FAX: 561.962.2101
|
April 10, 2020
Page 2
For purposes of rendering
this opinion, we have examined originals or copies (certified or otherwise identified to our satisfaction) of:
a. the
Registration Statement, in the form filed and to be filed with the Commission, and the exhibits filed or to be filed in connection
therewith, including the Prospectus Supplement;
b. the
Agreement;
c. the Second Amended and Restated Certificate of Incorporation of the Corporation, as amended, as certified by the Secretary of the Corporation;
d. the
Bylaws of the Corporation, as certified by the Secretary of the Corporation; and
e. resolutions of the Board of Directors of the Corporation, as attested to by the Secretary of the Corporation.
We have also examined
such other certificates of public officials, such certificates of executive officers of the Corporation and such other records,
agreements, documents and instruments as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.
In such examination,
we have assumed (i) the genuineness of all signatures, (ii) the legal capacity of all natural persons, (iii) the
authenticity of all documents submitted to us as originals, (iv) the conformity to original documents of all documents submitted
to us as certified, conformed or other copies and the authenticity of the originals of such documents and (v) that all records
and other information made available to us by the Corporation on which we have relied are complete in all material respects. As
to all questions of fact material to the opinion expressed herein, we have relied solely upon the above-referenced certificates
or comparable documents and upon the representations and warranties contained in the Agreement and other documents delivered pursuant
thereto, have not performed or had performed any independent research of public records and have assumed that certificates of or
other comparable documents from public officials dated prior to the date hereof remain accurate as of the date hereof.
Based on the foregoing,
we are of the opinion that the Shares, when issued pursuant to the terms of the Agreement against receipt by the Corporation of
the consideration specified therein, will be validly issued, fully paid and non-assessable.
The foregoing opinion
is limited to the laws of the State of Delaware, and we do not express any opinion herein concerning any other law.
April 10, 2020
Page 3
The opinion expressed
herein is rendered as of the date hereof and is based on existing law, which is subject to change. Where our opinion expressed
herein refers to events to occur at a future date, we have assumed that there will have been no changes in the relevant law or
facts between the date hereof and such future date. We do not undertake to advise you of any changes in the opinion expressed herein
from matters that may hereafter arise or be brought to our attention or to revise or supplement such opinions should the present
laws of any jurisdiction be changed by legislative action, judicial decision or otherwise.
Our opinion expressed
herein is limited to the matters expressly stated herein and no opinion is implied or may be inferred beyond the matters expressly
stated.
We hereby consent to
the use of this letter as an exhibit to the Registration Statement and to any and all references to our firm in the Prospectus
which is a part of the Registration Statement. In giving this consent, we do not admit that we are “experts” within
the meaning of Section 11 of the Securities Act or within the category of persons whose consent is required under Section 7
of the Securities Act.
|
|
Sincerely,
|
|
|
|
|
|
/s/ Duane Morris LLP
|